MedPlus Health Services shares tumbled after the company reported a weaker-than-expected Q1FY27. Despite healthy 21.9% revenue growth to ₹1,880 crore, investors were disappointed by the profitability miss. Brokerage Nomura maintained its ‘Buy’ rating, highlighting MedPlus’ long-term growth potential driven by its store expansion strategy.
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and credits belong to the original authors and publishers.